Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood test score may guide ovarian cancer treatment decisions

NCT ID NCT06660147

Knowledge-focused Sponsor: ARCAGY/ GINECO GROUP Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether a score called KELIM can predict how well ovarian cancer patients respond to maintenance treatment with PARP inhibitors after initial chemotherapy. Researchers will analyze data from 243 patients who took part in the PAOLA-1 trial. If KELIM proves useful, it could help doctors personalize treatment and avoid giving strong medications to those unlikely to benefit.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If KELIM proves reliable, doctors could better match ovarian cancer patients to PARP inhibitor treatment, avoiding unnecessary side effects and focusing therapy on those most likely to benefit.
What could go wrong
This is a retrospective analysis of existing data, not a new treatment trial. The KELIM score may not prove accurate enough to change clinical practice, and results may not apply to all patient groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

243 people

The number who actually took part.

Started

Dec 2023

Finished

Jan 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients randomised in the PAOLA-1 study : Patients with advanced FIGO stage IIIB-IV high grade serous or endometrioid ovarian, fallopian tube, or peritoneal cancer treated with standard first line treatment combining platinum based chemotherapy plus bevacizumab followed by a maintenance treatment by bevacizumab and Olaparib or placebo.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Patients randomised in the PAOLA-1 study - Exclusion Criteria:Opposition to the use of your data for research purposes. \-

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ovarian cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

ovarian cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ovarian cancer

Contacts and locations

Locations

  • CHRU Besançon - Hôpital Jean Minjoz

    Besançon, 25030, France

  • CHU Grenoble-Alpes - Site Nord (La Tronche)

    Grenoble, 38043, France

  • CHU de Poitiers - Hôpital de la Milétrie

    Poitiers, 86021, France

  • Centre Azuréen de Cancérologie

    Mougins, 06250, France

  • Centre Eugène Marquis

    Rennes, 35042, France

  • Centre François Baclesse

    Caen, 14076, France

  • Centre Hospitalier Départemental de Vendée

    La Roche-sur-Yon, 85925, France

  • Centre Hospitalier Princesse Grace

    Monaco, 98012, Monaco

  • Centre Jean Perrin

    Clermont-Ferrand, 63011, France

  • Clinique Francheville

    Périgueux, 24004, France

  • Clinique Pasteur

    Toulouse, 31300, France

  • Groupe Hospitalier Diaconesses - Croix Saint-Simon

    Paris, 75012, France

  • Gustave Roussy

    Villejuif, 94805, France

  • HCL - Centre Hospitalier Lyon Sud

    Pierre-Bénite, 69495, France

  • Hôpital Cochin

    Paris, 75014, France

  • Hôpital Européen Georges Pompidou

    Paris, 75015, France

  • Hôpital Privé du Confluent

    Nantes, France

  • ICL - Centre Alexis Vautrin

    Vandœuvre-lès-Nancy, 54519, France

  • ICO - Centre René Gauducheau

    Saint-Herblain, 44805, France

  • ICO Paul Papin

    Angers, 49055, France

  • Institut Curie

    Paris, 75248, France

  • Oncopole Claudius Regaud - IUCT Oncopole

    Toulouse, 31059, France

  • Polyclinique Bordeaux Nord

    Bordeaux, 33300, France

  • Sainte-Catherine Institut du Cancer Avignon-Provence

    Avignon, 84918, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.